Abstract
Serum levels of glial fibrillar acidic protein (GFAP) were analyzed in 317 patients with primary and metastatic tumors of the brain, 78 patients with neurological diseases, and 66 normal subjects. A significant increase in the basal level of GFAP was typical of patients with glioblastomas in comparison with other groups (patients with astrocytomas, cerebral metastases, benign tumors, non-tumor diseases, and healthy subjects). An association of GFAP levels with unfavorable prognosis of overall survival in patients with glioblastoma was revealed. The data attest to high specificity and sensitivity of GFAP as a biochemical marker of glioblastoma.
Keywords:
diagnosis; glial fibrillary acidic protein (GFAP); glioblastoma; neurological diseases of the brain; prognosis.
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Aged, 80 and over
-
Alzheimer Disease / blood
-
Alzheimer Disease / diagnosis
-
Alzheimer Disease / genetics
-
Astrocytoma / blood
-
Astrocytoma / diagnosis
-
Astrocytoma / genetics*
-
Astrocytoma / mortality
-
Biomarkers, Tumor / blood
-
Biomarkers, Tumor / genetics*
-
Brain / metabolism
-
Brain / pathology
-
Brain Neoplasms / blood
-
Brain Neoplasms / diagnosis
-
Brain Neoplasms / genetics*
-
Brain Neoplasms / mortality
-
Case-Control Studies
-
Female
-
Glial Fibrillary Acidic Protein / blood
-
Glial Fibrillary Acidic Protein / genetics*
-
Glioblastoma / blood
-
Glioblastoma / diagnosis
-
Glioblastoma / genetics*
-
Glioblastoma / mortality
-
Humans
-
Lymphatic Metastasis
-
Male
-
Middle Aged
-
Multiple Sclerosis / blood
-
Multiple Sclerosis / diagnosis
-
Multiple Sclerosis / genetics
-
Neuroglia / metabolism
-
Neuroglia / pathology
-
Parkinson Disease / blood
-
Parkinson Disease / diagnosis
-
Parkinson Disease / genetics
-
Prognosis
-
Survival Analysis
Substances
-
Biomarkers, Tumor
-
GFAP protein, human
-
Glial Fibrillary Acidic Protein